Drugs / Rogaratinib
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT04483505 | Nov 2020 → Apr 2023 | hormone receptor-positive breast cancer | CRIS Cancer Foundation | Completed | No outcome recorded |
| Phase 1 | NCT03788603 | Jan → Apr 2019 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03517956 | Jul 2018 → Feb 2021 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03473756 | May 2018 → Jul 2021 | urothelial carcinoma | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03484585 | Apr → May 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02592785 | Dec 2015 → Feb 2017 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01976741 | Dec 2013 → Mar 2019 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04595747 | May 2021 → Jul 2027 expected | gastrointestinal stromal tumor, sarcoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04040725 | Nov 2019 | urinary bladder cancer | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT04125693 | Oct 2019 → Feb 2021 | cancer | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT03762122 | Jul 2019 → Aug 2021 | non-small cell squamous lung carcinoma | Swiss Cancer Institute | Terminated | No outcome recorded Stop: Business |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT03410693 | May 2018 → Oct 2020 | transitional cell carcinoma | Bayer | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rogaratinib | “Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors” NCT02592785 ↗ |
| Known as | BAY1163877 | “Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With...” NCT04595747 ↗10“Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors” NCT02592785 ↗ “Rogaratinib (BAY 1163877; Bayer) is an oral pan-kinase inhibitor, which selectively inhibits FGFR1, FGFR2, FGFR3, and FGFR4.” NCT03762122 ↗ “Rogaratinib (BAY1163877) in Chinese Patients” NCT03788603 ↗ “Rogaratinib (BAY1163877) oral solution” NCT01976741 ↗ “Rogaratinib (BAY1163877)” NCT03410693 ↗ “Rogaratinib (BAY1163877)” NCT03473756 ↗ “Rogaratinib (BAY1163877)” NCT03484585 ↗ “Rogaratinib (BAY1163877)” NCT03517956 ↗ “Rogaratinib (BAY1163877)” NCT04125693 ↗ |
| Action | Inhibit | “rogaratinib potently and selectively inhibits the activity of FGFRs 1, 2, 3 and 4.” PMID 30807645 ↗ Mar 2019 |
| Modality | Small molecule | — CHEMBL3963485 ↗ |
| Route | Oral | “Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously” NCT03410693 ↗ |
| Target | FGFR1 | “rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor” PMID 36240478 ↗ Oct 2022 |